TBPH R&D to Revenue
Theravance Biopharma Inc · R&D to Revenue
TBPH R&D to Revenue
Latest reported22.73%period ending
TBPH Quarterly R&D/Revenue (0.00% → 22.73%)
Latest values, visible window
High-resolution chart · PNG
TBPH r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 22.7292% | |
| 32.9341% | |
| 15.1729% | |
| 40.5803% | |
| 40.0458% | |
| 74.4216% | |
| 49.9893% | |
| 54.9443% | |
| 69.8232% | |
| 61.8355% | |
| 51.2098% | |
| 50.2071% | |
| 82.7115% | |
| 156.715% | |
| 118.0558% | |
| 92.5548% | |
| 149.0226% | |
| 187.8524% | |
| 221.6647% | |
| 356.5257% | |
| 405.3972% | |
| 484.1481% | |
| 370.7795% | |
| 369.0146% | |
| 415.8049% | |
| 332.3583% | |
| 227.2111% | |
| 418.492% | |
| 177.434% | |
| 1,008.2053% | |
| 332.1408% | |
| 410.4456% | |
| 207.1094% | |
| 574.1676% | |
| 1,130.6977% | |
| 920.3041% | |
| 1,223.34% | |
| 1,314.059% | |
| 738.1061% | |
| 167.502% | |
| 586.1634% | |
| 193.7968% | |
| 832.3144% | |
| 283.8568% | |
| 425.806% | |
| 176.5551% | |
| 2,944.3126% | |
| 604.8611% | |
| 1,556.2542% | |
| 4,415.1323% | |
| 18,554.2857% | |
| 134,587.5% | |
| 608,000% | |
| 115,490.9091% | |
| 628.597% | |
| 0% |